Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Nephrology"
DOI: 10.1159/000527167
Abstract: Introduction: C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with poor prognosis and limited treatment options. Targeted inhibition of proximal AP through factor… read more here.
Keywords: inhibition; patients c3g; c3g mpgn; mpgn treated ... See more keywords